Just by typing on their mobile phone, MS patients can allow progression of their disease to be passively monitored and it allows for good adherence. Tapping speed may be a useful tool for MS monitoring and can help to detect the phenotypes with progressive disease patterns
Continuously acquired smartphone keyboard interactions have shown their potential for the monitoring of various neurodegenerative diseases, including Parkinson’s disease and dementia . Dr Juan Luis Chico-Garcia (Hospital Ramon y Cajal, Spain) and colleagues prospectively studied the potential of this approach in MS, in their comprehensive MS centre .
The researchers developed their own software that MS patients in their institution could download on their mobile phone. They set out to study the accuracy and reliability of this “in house” application and to correlate tapping speed with clinical MS scales. Median values in the first week of assessment were compared through Spearman’s Rho and linear regression including Expanded Disability Status Scale (EDSS) score, 9-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FWT), and Processing Speed Test (PST) CogEval® raw scores (RS) and Z score.
Of the 50 participants, 31 (62%) were women, median age was 45 years and they had an EDSS score of 2.0 (IQR 1.5–4.5), 80% had relapsing-remitting MS, 12% had secondary-progressive MS, 8% had primary-progressive MS, and 18% used no DMT.
Tapping speed was found to have a strong negative correlation with EDSS score (r=-0.54; P=0.0003), 9HPT (r=-0.54; P=0.002), and T25FWT (r=-0.65; P=0.0007). Tapping speed positively correlated with baseline PST RS (r=0.57; P<0.00001) and PST Z score (r=0.43; P=0.0003) but was negatively correlated with time since MS first symptoms (r=-0.39; P=0.003). Tapping speed was lower in participants diagnosed with secondary progressive MS than with relapsing-remitting MS (P=0.008), with an area under the curve of 0.84. Limitations of the study were low sample size, underrepresentation of progressive phenotypes, and the influence of age.
Tapping speed may thus be a useful tool for MS monitoring and may help to detect the progressive phenotypes of the disease.
- Arroyo-Gallego T, et al. J Med Internet Res. 2018 Mar 26;20(3):e89.
- Chico Garcia JL, et al. Tapping speed in smartphone is useful for detection of progressive multiple sclerosis. Abstract O074, ECTRIMS 2022, 26–28 October, the Netherlands.
Copyright ©2022 Medicom Medical Publishers
« Dimethyl fumarate reduces the risk of a first clinical event in RIS Next Article
Efficacy of DMTs fades away in secondary progressive MS »
Table of Contents: ECTRIMS 2022
Letter from the Editor
ECTRIMS 2022 Highlights Podcast
Diagnosis and Prediction of Disease Course
A case for including optic nerve lesions in the McDonald criteria
Cerebrospinal fluid kappa-free light chains for MS diagnosis
Early, non-disabling relapses increase disability accumulation
Physical impairment is present before perceived MS onset
Chronic active MS lesions respond poorly to anti-CD20 antibodies
Treatment: Trials & Strategies
Dimethyl fumarate reduces the risk of a first clinical event in RIS
How and when to make a timely switch to high-efficacy DMT
Comparing real-world effectiveness of DMTs
Study fails to show non-inferiority of rituximab to ocrelizumab
Autologous haematopoietic stem cell transplantation versus DMTs
Stem cell transplantation not superior to natalizumab in progressive MS
Efficacy of DMTs fades away in secondary progressive MS
Smartphone tapping can help detect progressive MS
Early treatment with DMT effective in paediatric-onset MS
Fingolimod in paediatric MS: results of up to 6 years
Switching treatment after initial platform injectable DMT: real-world data
Pregnancy and infant outcomes in women receiving ocrelizumab
New safety data of anti-CD20 mAbs around pregnancy
MS activity and pregnancy outcomes after long-term use of natalizumab
Ravulizumab significantly reduced relapses in AQP4+ NMOSD
NMOSD patients are cognitively impaired regardless of serostatus
Evidence-based consensus on pregnancy in NMOSD
COVID-19 and MS: lessons learned thus far
Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes
Humoral and cellular immune responses after SARS-CoV-2 vaccination
Re-myelination strategies in MS still pose many unanswered questions
MS associated with a broader Epstein-Barr virus specific T-cell receptor repertoire
Cognitive rehab and mindfulness reduce cognitive complaints in MS
Predictive value of CSF Aβ and tau proteins in MS
Therapeutic potential of anti-MOSPD2 monoclonal antibodies